Rezolute (RZLT) said it received FDA clearance for Investigational New Drug application for RZ358 to treat hypoglycemia in patients with tumor hyperinsulinism. The company is initiating start-up activities for the study which will be primarily conducted in the U.S. and patient enrollment is planned to commence in the first half of 2025.
Ersodetug is also being studied in an ongoing global, Phase 3 clinical trial in patients with congenital HI. Topline data from the study is expected in mid-2025.
Shares of Rezolute are down 6% in pre-market trade on Monday.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.